In Silico design of AVP (4–5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles

RT @MarkQuarter: @PaperbirdsN "The AVP (4-5) dipeptide corresponds to the N-terminal fragment of the major vasopressin metabolite AVP (4-9)…

@PaperbirdsN "The AVP (4-5) dipeptide corresponds to the N-terminal fragment of the major vasopressin metabolite AVP (4-9), has a neuroprotective effect and used in the treatment of Alzheimer's and Parkinson's disease" https://t.co/G5IpG7lwCQ

The experimental medium of peptide-loaded chitosan nanoparticles was created for the first time with an in-silico system, and molecular dynamics studies carried out the stability of the peptide in this medium. The binding sites of…https://t.co/DspSizloC5 h

In Silico design of Arginine-vasopressin (AVP) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles https://t.co/UwuWXV2q7g #AVP #Parkinsons #Alzheimers #Neurology #nanoparticles #Pharmaceutical #pharmaceutics #nanotechno

RT @Ingentium_PD: In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles. ht…

In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles. https://t.co/LvDPW5myxP

In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles. https://t.co/bQpEfnMWjL

In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles. https://t.co/Os79Rt29Tv

New article: In Silico design of AVP (4-5) peptide and synthesis, characterization and in vitro activity of chitosan nanoparticles. https://t.co/UvPs9qnkse #alzheimers #neurology